Xaira Therapeutics pricing
A buyer cannot currently determine what is for sale. No business model, partnership terms, licensing arrangement, revenue or route of external access has been publicly disclosed, and Xaira names no pharmaceutical collaboration. What is public is the capital: more than $1 billion committed at the April 2024 launch, described as the largest initial funding commitment in ARCH Venture Partners history, co led by ARCH and Foresite Labs with F-Prime, NEA, Sequoia Capital, Lux Capital and Lightspeed participating, at a reported valuation around $4 billion.
How Xaira Therapeutics pricing works
- Pricing model
- No commercial model disclosed. Xaira publishes no partnership, licensing or service structure.
Governance is equally visible, with a board including former FDA Commissioner Scott Gottlieb, Nobel laureate Carolyn Bertozzi and former Johnson & Johnson chief executive Alex Gorsky. This is capital transparency without commercial transparency, and the distinction matters: knowing who funded a company is not knowing how to work with it.
Xaira Therapeutics pricing against its alternatives
Published prices for Xaira Therapeutics and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.
- XXaira TherapeuticsNot applicable
- RRecursionNot applicable
- IImmunaiNo published price
- DDeep GenomicsNo published price
- EEikon TherapeuticsNot applicable
- IimmunitoAINo published price
- TTerray TherapeuticsNot applicable
- NNumerion LabsNo published price
- IinsitroNot applicable
Xaira Therapeutics pricing, answered
How much does Xaira Therapeutics cost?
Xaira Therapeutics does not publish a price. A buyer cannot currently determine what is for sale. No business model, partnership terms, licensing arrangement, revenue or route of external access has been publicly disclosed, and Xaira names no pharmaceutical collaboration.